AU2010251703B2 - Use of dynamin ring stabilizers - Google Patents

Use of dynamin ring stabilizers Download PDF

Info

Publication number
AU2010251703B2
AU2010251703B2 AU2010251703A AU2010251703A AU2010251703B2 AU 2010251703 B2 AU2010251703 B2 AU 2010251703B2 AU 2010251703 A AU2010251703 A AU 2010251703A AU 2010251703 A AU2010251703 A AU 2010251703A AU 2010251703 B2 AU2010251703 B2 AU 2010251703B2
Authority
AU
Australia
Prior art keywords
dynamin
ring
stabilizer
actin
rings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010251703A
Other languages
English (en)
Other versions
AU2010251703A1 (en
Inventor
Phillip J. Robinson
Sanja Sever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children's Medical Research Institute
Original Assignee
Childrens Medical Research Inst
Children's Medical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Research Inst, Children's Medical Research Institute filed Critical Childrens Medical Research Inst
Publication of AU2010251703A1 publication Critical patent/AU2010251703A1/en
Application granted granted Critical
Publication of AU2010251703B2 publication Critical patent/AU2010251703B2/en
Assigned to CHILDREN'S MEDICAL RESEARCH INSTITUTE reassignment CHILDREN'S MEDICAL RESEARCH INSTITUTE Request for Assignment Assignors: CHILDREN'S MEDICAL RESEARCH INSTITUTE, THE GENERAL HOSPITAL CORPORATION
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2010251703A 2009-05-21 2010-05-21 Use of dynamin ring stabilizers Ceased AU2010251703B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18026109P 2009-05-21 2009-05-21
US61/180,261 2009-05-21
PCT/AU2010/000677 WO2010132959A1 (en) 2009-05-21 2010-05-21 Use of dynamin ring stabilizers

Publications (2)

Publication Number Publication Date
AU2010251703A1 AU2010251703A1 (en) 2011-12-08
AU2010251703B2 true AU2010251703B2 (en) 2015-12-24

Family

ID=43125677

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010251703A Ceased AU2010251703B2 (en) 2009-05-21 2010-05-21 Use of dynamin ring stabilizers

Country Status (8)

Country Link
US (1) US8809386B2 (enExample)
EP (1) EP2432465B1 (enExample)
JP (1) JP2012527407A (enExample)
CN (1) CN102481280A (enExample)
AU (1) AU2010251703B2 (enExample)
BR (1) BRPI1010941B1 (enExample)
CA (1) CA2762600C (enExample)
WO (1) WO2010132959A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2782643A1 (en) * 2011-11-23 2014-10-01 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Androgen receptor ligands
WO2014063205A1 (en) * 2012-10-26 2014-05-01 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
JP2017518312A (ja) * 2014-06-05 2017-07-06 ユニバーシティ・オブ・カンザス マルメリン類似体および癌治療における使用方法
CN105510592A (zh) * 2014-09-26 2016-04-20 中国医学科学院基础医学研究所 梗阻性肾病的蛋白标志物
US11028138B2 (en) * 2016-07-02 2021-06-08 Virongy L.L.C. Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens
CN113801872A (zh) * 2021-10-11 2021-12-17 杭州师范大学 一种精准调控组装制备稳定酶蛋白环的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049009A1 (en) * 2003-11-21 2005-06-02 The University Of Newcastle Research Associates Limited Methods and agents for inhibiting dynamin-dependent endocytosis
WO2007056435A2 (en) * 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107736A (en) 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
WO2001064880A2 (en) 2000-02-28 2001-09-07 Millennium Pharmaceuticals, Inc. Human dynamin 40322
CN1938013A (zh) * 2003-11-21 2007-03-28 纽卡斯尔大学研究协会有限公司 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂
US9144594B2 (en) 2005-11-08 2015-09-29 University Of Miami Cathepsin L mediated diseases and associated methods and products
WO2009034464A2 (en) 2007-09-12 2009-03-19 Newcastle Innovation Limited Indole related compounds with physiological activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049009A1 (en) * 2003-11-21 2005-06-02 The University Of Newcastle Research Associates Limited Methods and agents for inhibiting dynamin-dependent endocytosis
WO2007056435A2 (en) * 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABBAN, C.A. et al. "HPV16 and BPV1 Infection Can Be Blocked by the Dynamin Inhibitor Dynasore" Am J Ther (2008) Vol.15 No.4 pages 304 to 311 *
HILL, T. et al. "Small Molecule Inhibitors of Dynamin I GTPase Activity: Development of Dimeric Tyrphostins" J Med Chem (2005) Vol.48 pages 7781 to 7788 *
OTSUKA, A. et al. "Dynamin 2 is required for actin assembly in phagocytosis in Sertoli cells" Biochemical and Biophysical Research Communications (2009) Vol.378 pages 478 to 482 *

Also Published As

Publication number Publication date
EP2432465A1 (en) 2012-03-28
BRPI1010941B1 (pt) 2021-06-22
US20120122968A1 (en) 2012-05-17
AU2010251703A1 (en) 2011-12-08
CA2762600C (en) 2018-05-15
US8809386B2 (en) 2014-08-19
EP2432465B1 (en) 2015-07-22
EP2432465A4 (en) 2013-01-02
CA2762600A1 (en) 2010-11-25
WO2010132959A1 (en) 2010-11-25
JP2012527407A (ja) 2012-11-08
CN102481280A (zh) 2012-05-30
BRPI1010941A2 (pt) 2019-04-09

Similar Documents

Publication Publication Date Title
CA2762600C (en) Use of dynamin ring stabilizers
Garbes et al. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate
JP7411967B2 (ja) 肺血管疾患を治療するための組成物および方法
US20160257957A1 (en) Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
Kakinen et al. Single-molecular hetero-amyloidosis of human islet amyloid polypeptide
Foley et al. Trapping and characterization of nontoxic Aβ42 aggregation intermediates
Ayala et al. (Bio) chemical strategies to modulate amyloid-β self-assembly
Lin et al. TFEB agonist clomiphene citrate activates the autophagy-lysosomal pathway and ameliorates Alzheimer's disease symptoms in mice
Wiśniewski et al. Discovery of potent, selective, and short-acting peptidic V2 receptor agonists
Mruthinti et al. The induction of surface β-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by advanced glycation end products
EP4081220A1 (en) Combination of a proteasome inhibitor and a hdac inhibitor and its use for the treatment of genetic diseases linked to a protein conformational disorder
AU2014357521B2 (en) Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
US9045434B1 (en) Compositions and methods of treatment for myocilin glaucoma by selectively inhibiting GRP94
US20120004175A1 (en) Inhibitors of nf-kb activity
US20240083951A1 (en) Targeting alpha2delta-1-bound glutamate receptors for treating diseases and disorders
EP1691800A1 (en) Methods and agents for inhibiting dynamin-dependent endocytosis
Priyanka et al. Native state stabilization of amyloidogenic proteins by kinetic stabilizers: inhibition of protein aggregation and clinical relevance
KR20250028426A (ko) 변형된 융합 단백질 및 핵산 작제물
KR100833728B1 (ko) 칼시뉴린의 항상적 활성화 저해제
US20250074951A1 (en) Compositions and methods for altering amyloid precursor protein (app) processing
US6878521B1 (en) Fibril-blocking peptide, a method for preventing fibril formation
JP2018177685A (ja) 細胞膜の損傷修復促進剤
Trofimenko Novel insights into direct translocation and endocytosis of cell-penetrating peptides
Abrar Targeting p62 Palmitoylation as a Potential Therapeutic Strategy towards Huntington Disease
Cooley Dysregulated Membrane Trafficking and the Development of Pancreatitis

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CHILDREN'S MEDICAL RESEARCH INSTITUTE

Free format text: FORMER APPLICANT(S): CHILDREN'S MEDICAL RESEARCH INSTITUTE; THE GENERAL HOSPITAL CORPORATION

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired